Synonyms: CDP-7657 | CDP7657 | DZP
Compound class:
Antibody
Comment: Dapirolizumab pegol (CDP7657) is a pegylated monovalent Fab' immunomodulator that targets CD40 ligand [1]. It was developed by UCB Pharma. Removal of the Fc domain prevented the increased risk of thrombotic events observed with an intact mAb.
|
Classification | |
Compound class | Antibody |
International Nonproprietary Names | |
INN number | INN |
9869 | dapirolizumab pegol |
Synonyms |
CDP-7657 | CDP7657 | DZP |
Database Links | |
Specialist databases | |
IMGT/mAb-DB | 481 |
Other databases | |
CAS Registry No. | 1416147-64-2 (source: WHO INN record) |
ChEMBL Ligand | CHEMBL2109478 |
GtoPdb PubChem SID | 434122183 |
Search PubMed clinical trials | dapirolizumab pegol |
Search PubMed titles | dapirolizumab pegol |
Search PubMed titles/abstracts | dapirolizumab pegol |